Dallah Healthcare Co. · TADAWUL:4004
Dallah Healthcare — Q3 2025 Earnings Presentation
26 slides from Dallah Healthcare's earnings presentation, 2025
Slide 1: Dallah Healthcare Co. Q3-2025
Dallah Healthcare Co. Q3- 2025
Slide 2: Today's Speakers and Agenda
Today’s Speakers and Agenda 1. About us 2. Business Review 3. Financial Review Abdulaziz Alwohaibi Amine A.Hariz Omar Aljabari Saud Alraqraq Chief Operating Officer Chief Financial Officer Chief Commercial Officer Business Development Director
Slide 3: DHC's mission and vision, guided by core values
DHC’s mission and vision … … guided by core values Mission Values To deliver excellent healthcare services Care and respect for our patients, which are consistent with our values and their needs and our society with the expectation of our patients, society, and partners Commitment to professional et
Slide 4: Dallah Healthcare Company offers an attractive investment opportunity
DHC has long been established in KSA and has shown year-on-year growth DHC has a strong product portfolio, consistently growing to address the evolving needs of patients Dallah Healthcare Company offers an DHC has numerous certifications positioning it at the forefront in terms of service excellence
Slide 5: History: DHC has a long legacy in the healthcare space in KSA
Dallah Hospital- 1987 Al Nakheel Dallah Pharma 2002 Dallah Ob-gyne 2007 2012 DHC listing Dallah Pediatrics 2013 Jordanian Pharmaceuticals Co. Afyaa Al Nakheel 2014 and DMRF North clinics 2015 quite rapidly both organically and inorganically Dallah Hospital- 2018 Namar Dallah Al Nakheel Meras Arabia
Slide 6: DHC owns and directly operates five categories of companies
Dallah Health Company Portfolio Today, DHC owns and directly operates five categories of companies while also engaging in active management of portfolio investments Owned & operated by DHC Portfolio investments (ownership share, %) Hospitals Clinics Dr. MRF Hospital Fully equipped private hospital,
Slide 7: DHC's longstanding presence in KSA and integrated portfolio of services
12 +2,560 Healthcare Facilities Beds DHC’s longstanding presence in KSA and integrated portfolio of services position it 31% 48% Patients Volume CAGR Net Profit as a leader in service FY20-24 CAGR FY20-24 excellence, quality, and patient safety 5 +207 Medical specialties Cities around KSA & subspeci
Slide 8: Awards and Honours
ICHOM “Most Contributing Leading Hospital” The 1st Saudi hospital to receive the new version of ICHOM Accreditation By CHI “Top Healthcare Leaders in the “Excellence in Patient Satisfaction” Middle East for 2025” Awards and Honours by the Global Patient Experience For our CEO from Forbes Middle East
Slide 9: With +2,560 beds, DHC aims to further expand to meet future demand
Dallah Health Company Portfolio With +2,560 beds, DHC aims to further expand to meet future demand Combined current capacity at +2,560 beds across DHC's operational entities and investments Companies owned & operated by 540 300 475 274 4 3 beds beds beds beds Location Cities DHC Portfolio investment
Slide 10: Future Projects
Dallah Health Company Portfolio Future Projects Dallah Alarid Hospital Wahat Al-Nakheel Real Estate Fund • Land: 45,000 sqm • DHC, Dallah Real Estate, Aljazira Capital, • Built-up area: 87,300 sqm and Tatweer signed MoU to establish a private real estate fund. • 250 Beds • An estimated value exceedi
Slide 11: DHC's presence across the Kingdom of Saudi Arabia
DHC's presence Al Khobar across the �)« Riyadh Al Hofouf Kingdom of ÷U�d�« ·uH�« Saudi Arabia Jeddah …b� Makkah W�dJ*« WJ� 10
Slide 12: Array of medical services offered by DHC hospitals
Dallah Health Company Portfolio The array of medical services offered by DHC hospitals extends across various specialties, complemented by supplementary support services 207+ Medical specialties and subspecialties 4+ key Ancillary Services Medical services under the following therapy areas: Suppleme
Slide 13: Consistent patient volume growth over the past 5 years
Dallah Health Company Portfolio Over the past 5 years, DHC's hospitals have demonstrated consistent patient volume growth, a trend evident when comparing 9M-24 with 9M-25. Patient volume (in 000s) CAGR 29% 37% 31% 2,839 2,737 2,684 2,252 1,800 2,086 968 991 721 2020 2021 2022 2023 2024 Q3-24 Q3-25 9
Slide 14: Certifications, accreditations, and awards for service excellence and patient safety
Dallah Health Company Accreditations When addressing service excellence and patient safety, DHC has acquired several well-regarded certifications, accreditations, and awards One of the first hospitals in Dallah Hospital laboratory Dallah Hospitals catering Saudi Arabia awarded JCI certified by the C
Slide 15: DHC's Journey to Value-Based Healthcare
DHC’ Journey to Value-Based Healthcare DHC's is dedicated to leading the way in VBHC, ultimately delivering greater value and improved health outcomes for our patients Key initiatives: Pilot Programs Strategic Collaborations Future Focus • PROM & PREM with a Major Insurer • The Center for Value in H
Slide 16: Well-defined 5-year strategy for the diversified portfolio
Dallah Health Company Growth Strategy & Leadership DHC's future growth is supported by its well-defined 5-year strategy anchored around a coherent direction for the diversified portfolio Deep-dive included in the next slides Operating companies Investments Become a one-stop shop for VIP/A privately
Slide 17: Becoming a one-stop high-end service provider
Dallah Health Company Growth Strategy & Leadership To become a 'one-stop high-end' service provider, DHC is selectively specializing as well as expanding into clinics, telemedicine, post-acute care and homecare Value One-stop-shop high-end provider First point of contact from the cradle to the grave
Slide 18: Strong financial performance during 9M-25
Dallah Health Company Financial Performance DHC has experienced a strong financial performance during 9M-25 Key consolidated financial metrics (SAR M) 9M-24 9M-25 Revenues 2,397 23% 2,956 EBITDA 585 17% 685 EBIT 480 9% 522 Net Profit 383 12% 429 Net Profit attributable to owners 357 18% 422 Earnings
Slide 19: Current quarterly revenue run-rate at double that of FY21
Dallah Health Company Financial Performance Current quarterly revenue run-rate in FY25 stands at double that of FY21 Revenues (SAR M) CAGR 23% 25% 25% 3,206 2,943 2,488 1,061 2,105 2,956 848 2,397 1,318 2020 2021 2022 2023 2024 9M-2024 9M-2025 Q3-2024 Q3-2025 18
Slide 20: Q2 and Q3 2025 recorded the highest revenues ever
Dallah Health Company Financial Performance Second and third quarters of 2025 recorded the highest revenues ever achieved by the Company Revenues (SAR M) 1,062 1,061 848 833 806 809 784 765 750 717 670 Q1-23 Q2-23 Q3-23 Q4-23 Q1-24 Q2-24 Q3-24 Q4-24 Q1-25 Q2-25 Q3-25 19
Slide 21: Transitory pressure on gross margin due to the acquisition
Dallah Health Company Financial Performance Transitory pressure on gross margin due to the acquisition, with Dallah Al-Khobar profitability now ahead of management’s pre-transaction assessment Gross Profit (SAR M) CAGR 15% 18% 28% 1600 1600 1600 38% 40% 38% 40% 38% 40% 36% 36% 37% 36% 1400 1400 36%
Slide 22: Operational excellence compounding growth with rising margins (EBIT)
Dallah Health Company Financial Performance DHC’s operational excellence has compounded growth in value with rise in profitability margins, unlocking substantial shareholder value EBIT (SAR M) CAGR 1000 9% 30% -1% 45% 800 19% 900 19% 25% 17% 800 700 16% 16% 17% 800 2 700 20% 20% 600 15% 20% 1 610 18
Slide 23: EBITDA margin highly resilient post-acquisition
Dallah Health Company Financial Performance EBITDA margin highly resilient post-acquisition EBITDA (SAR M) CAGR 17% 7% 34% 1000 1000 30% 1000 30% 30% 900 900 900 23% 25% 24% 23% 800 25%24% 25% 800 800 21% 21% 21% 21% 700 751 700 700 20% 20% 20% 18% 685 600 630 600 600 585 500 500 15% 500 15% 15% 514
Slide 24: Earnings growth shows strong momentum since 2020
Dallah Health Company Financial Performance Earnings growth shows strong momentum since 2020, with 9M-25 net profit exceeding the full-year net profit of FY23 at a higher net margin Net Profit (SAR M) CAGR 12% 7% 48% 600 600 17% 16% 600 17%16% 17 15% 15% 15% 15% 15 14% 14% 13% 14% 500 13% 500 500 13
Slide 25: Transient surge in debt after the transaction, with long-term deleveraging
Dallah Health Company Financial Performance Transient surge in debt after the transaction, with consistent long-term deleveraging Net debt-to-EBITDA and Gearing ratio 5.9x 3.7x 3.3x 2.6x 2.3x 2.3x 3.4x 79% 76% 69% 3,033 48% 46% 67% 46% 1,697 1,731 1,659 1,659 1,384 1,715 751 630 890 514 751 449 234
Slide 26: Q&A
Q&A